2nd Structure-Based Drug Design Summit
June 3–5, 2025
Harnessing Integrative Structural Biology Techniques (NMR, X-Ray Crystallography, Cryo-EM, & Cryo-ET) to Determine 3D Structures of Pharmacologically Relevant Targets & Propel Drug Design Across Modalities
With tightening budgets and increasing pressure to de-risk R&D, pharma and biotech are shifting their focus toward smarter, more efficient drug design. Companies are investing more in enabling technologies—from computational modeling and AI-driven predictions to structural biology techniques like Cryo-EM, NMR, and X-ray crystallography—to improve rational drug design and enhance decision-making early in discovery.
While AI-powered structure prediction is transforming the landscape—recognized by the 2024 Nobel Prize for Google DeepMind’s AlphaFold2— its true impact depends on experimental validation. The ability to integrate computational insights with high-resolution structural data is now essential for unlocking complex targets and accelerating drug discovery.
Cryo-EM continues to push the limits of resolution for complex targets and Cryo-ET is emerging as a potential game-changer for biopharma - the future of structure-based drug design is here.
The 2nd Structure-Based Drug Design Summit is the only industry-dedicated meeting bringing together the latest advancements in integrative structural biology and computational tools to accelerate early drug discovery. Across three days of expert-led discussions and case studies, you’ll gain insights into how leading scientists are leveraging Cryo-EM, NMR, X-ray crystallography, and AI to solve high-value targets and drive rational drug design across small molecules, peptides, biologics, and vaccines.
With coverage of design of TPDs, molecular glues, vaccines, antibodies, and mRNA, GPCRs and membrane protein targeting therapeutics plus much more!
The field is evolving—don’t get left behind. Expand your network and join 80+ structural biologists, medicinal chemists, protein engineers, and computational chemists in Boston this June and be part of the next wave of structure-based drug design innovation.
